Publications by authors named "Mark Day"

Claim this Profile
T
TRIM29 promotes bladder cancer invasion by regulating the intermediate filament network and focal adhesion.
Yin Wang, Nicole A Jerome, Alan J Kelleher, Marian L Henderson, Mark L Day

Oncogene· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of biological soil crusts at the soil surface influences the persistence and movement of crop protection products.
Laurence Hand, Mark C J Day, Carol Nichols, Hendrik Schäfer, Samantha Marshall

Sci Total Environ· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The molecular mechanism of ambrosin-induced cytotoxicity of human breast cancer and bladder cancer cells.
Layla El-Sawy, John R Rubin, Luke Broses, Christopher Patsalis, Marian L Henderson, Kathleen C Day, Mark L Day

J Biol Chem· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrative Drug Screening and Multiomic Characterization of Patient-derived Bladder Cancer Organoids Reveal Novel Molecular Correlates of Gemcitabine Response.
Nathan M Merrill, Samuel D Kaffenberger, Liwei Bao, Nathalie Vandecan, Laura Goo, Mark L Day

Eur Urol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of circulating tumor cells in patients with metastatic bladder cancer utilizing functionalized microfluidics.
Zeqi Niu, Molly Kozminsky, Kathleen C Day, Luke J Broses, Marian L Henderson, Mark L Day

Neoplasia· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TRIM29 promotes bladder cancer invasion by regulating the intermediate filament network and focal adhesion.
Phillip Palmbos, Yin Wang, Nicole Jerome, Alan Kelleher, Marian Henderson, Mark Day

Res Sq· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Path of Least Resistance.
Sandeep S Jalli, Mark T Day, Tyler D Earley, Ross A Downey

JACC Case Rep· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MEK is a promising target in the basal subtype of bladder cancer.
Nathan M Merrill, Nathalie M Vandecan, Kathleen C Day, Phillip L Palmbos, Mark L Day

Oncotarget· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multiparameter urine analysis for quantitative bladder cancer surveillance of orthotopic xenografted mice.
Xiaotian Tan, Luke J Broses, Menglian Zhou, Kathleen C Day, Wenyi Liu, Mark L Day

Lab Chip· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ATDC mediates a TP63-regulated basal cancer invasive program.
Phillip L Palmbos, Yin Wang, Armand Bankhead Iii, Alan J Kelleher, Lidong Wang, Mark L Day

Oncogene· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A surgical orthotopic approach for studying the invasive progression of human bladder cancer.
Guadalupe Lorenzatti Hiles, Angelica L Cates, Layla El-Sawy, Kathleen C Day, Luke J Broses, Mark L Day

Nat Protoc· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications.
Daniel H Hovelson, Aaron M Udager, Andrew S McDaniel, Petros Grivas, Phillip Palmbos, Kathleen C Day, Mark L Day

Eur Urol· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Delta Alert: Expanding Gerotrauma Criteria to Improve Patient Outcomes: A 2-Year Study.
Lynn L Wiles, Mark D Day

J Trauma Nurs· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
3
3-D Cell Culture System for Studying Invasion and Evaluating Therapeutics in Bladder Cancer.
Yin Wang, Mark L Day, Diane M Simeone, Phillip L Palmbos

J Vis Exp· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular Correlates of Responses to Dacomitinib and Afatinib in Bladder Cancer.
Shuzo Tamura, Yin Wang, Brendan Veeneman, Daniel Hovelson, Armand Bankhead, Kathleen C Day, Mark L Day

Bladder Cancer· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Delta Alerts: Changing Outcomes in Geriatric Trauma.
Lynn L Wiles, Mark D Day, LeAnna Harris

J Trauma Nurs· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HER2 and EGFR Overexpression Support Metastatic Progression of Prostate Cancer to Bone.
Kathleen C Day, Guadalupe Lorenzatti Hiles, Molly Kozminsky, Scott J Dawsey, Alyssa Paul, Mark L Day

Cancer Res· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ADAM15 Is Functionally Associated with the Metastatic Progression of Human Bladder Cancer.
Guadalupe Lorenzatti Hiles, Amanda Bucheit, John R Rubin, Alexandra Hayward, Angelica L Cates, Kathleen C Day, Mark L Day

PLoS One· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Utility of Impulsive Bias and Altered Decision Making as Predictors of Drug Efficacy and Target Selection: Rethinking Behavioral Screening for Antidepressant Drugs.
Gerard J Marek, Mark Day, Thomas J Hudzik

J Pharmacol Exp Ther· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma.
Maha Hussain, Stephanie Daignault, Neeraj Agarwal, Petros D Grivas, Arlene O Siefker-Radtke, Kathleen C Day, Mark L Day

Cancer· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The E2F1/DNMT1 axis is associated with the development of AR negative castration resistant prostate cancer.
Conrad David Valdez, Lakshmi Kunju, Stephanie Daignault, Kirk J Wojno, Mark L Day

Prostate· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the antitumor activity of dacomitinib in models of human bladder cancer.
Petros D Grivas, Kathleen C Day, Andreas Karatsinides, Alyssa Paul, Nazia Shakir, Mark L Day

Mol Med· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Imaging conditioned fear circuitry using awake rodent fMRI.
Nichola M Brydges, Heather C Whalley, Maurits A Jansen, Gavin D Merrifield, Emma R Wood, Mark Day

PLoS One· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab.
Suthinee Ithimakin, Kathleen C Day, Fayaz Malik, Qin Zen, Scott J Dawsey, Mark L Day

Cancer Res· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
How many dendritic cells are required to initiate a T-cell response?
Susanna Celli, Mark Day, Andreas J Müller, Carmen Molina-Paris, Grant Lythe

Blood· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis